RxDoctor Payments DataLook up a doctor →

Lisa Myers, MD

Endocrinology, Diabetes & Metabolism · Germantown, TNNPI 1992768204

Payments from drug & device makers

$609,057in general payments, 2019–2025

Across 2,347 payments — averaging $259.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$210K
  • Abbott$96K
  • AstraZeneca$68K
  • Lilly USA, LLC$66K
  • Dexcom, Inc.$55K
  • Johnson & Johnson$25K
  • plus $88K from 53 others

What the payments were for

  • Consulting fees$11,7432%
  • Speaking & faculty fees$477,08978%
  • Travel & lodging$65,37911%
  • Food & beverage$54,5369%
  • Education$860%
  • Gifts$590%
  • Other$1650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk449$210,342
Abbott261$96,040
AstraZeneca(2 entities)135$68,197
Lilly USA, LLC276$65,772
Dexcom, Inc.127$55,343
Johnson & Johnson40$25,298
Amarin Pharma, Inc.72$18,699
Chiesi USA, Inc.20$16,226
Amryt Pharma Holdings Ltd21$15,579
Mannkind Corporation112$9,515
Cequr Corporation5$6,263
Amgen(2 entities)109$2,778
Corcept Therapeutics73$2,718
Medtronic(2 entities)32$2,013
Bayer53$1,492
Xeris Pharmaceuticals, Inc.67$1,406
Boehringer Ingelheim80$1,405
Sanofi-aventis U.S. LLC53$1,195
Insulet Corporation57$1,147
AbbVie57$841
Esperion Therapeutics, Inc.21$791
Sequel Med Tech, LLC13$549
BETA Bionics, Inc.5$488
Merck31$454
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC24$397
Tandem Diabetes Care, Inc.12$360
Ascensia Diabetes Care US Inc.15$354
IBSA Pharma Inc.10$285
Nevro Corp.9$250
Globus Medical3$233
Pfizer13$220
Madrigal Pharmaceuticals3$198
Companion Medical, Inc.2$172
Kyowa Kirin, Inc.4$171
Kowa Pharmaceuticals America, Inc.11$158
Ascendis Pharma Endocrinology Inc4$157
Radius Health, Inc.5$145
RGH Enterprises LLC1$140
Intercept Pharmaceuticals, Inc.1$125
Currax Pharmaceuticals LLC9$124
Janssen Scientific Affairs, LLC2$111
Amneal Pharmaceuticals LLC6$111
Recordati_rare_diseases_inc.5$108
Bausch & Lomb Americas Inc.1$99
Novartis5$93
Lifescan, Inc.5$74
Shire North American Group Inc4$59
Ionis Pharmaceuticals, Inc.2$48
Nalpropion Pharmaceuticals LLC3$48
Amphastar Pharmaceuticals, Inc.3$46
Ultragenyx Pharmaceutical Inc.2$45
GRT US Holding, Inc.3$44
Endo Pharmaceuticals Inc.2$35
Takeda Pharmaceuticals U.S.A., Inc.2$31
Acadia Pharmaceuticals Inc1$20
EUSA Pharma (US) LLC1$18
Medicure Pharma Inc.1$13
Vivus LLC1$11
Grace Medical, Inc.3$0

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$609,057 in reported general payments places this provider in the 85th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee

Medicare billing

Part B allowed, 2024
$186,566
Medicare patients
498
Services billed
7,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide693$805,923
MounjaroTirzepatide258$312,278
FarxigaDapagliflozin Propanediol245$267,553
TrulicityDulaglutide208$262,697
JardianceEmpagliflozin159$158,135
AfrezzaInsulin Regular, Human35$101,848
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/782$77,577
MycapssaOctreotide Acetate15$72,721
Fiasp FlextouchInsulin Aspart (Niacinamide)63$54,062
Tresiba Flextouch U-200Insulin Degludec66$45,514
VascepaIcosapent Ethyl49$43,723
JanuviaSitagliptin Phosphate45$43,202
Tresiba Flextouch U-100Insulin Degludec76$41,996
Novolog FlexpenInsulin Aspart158$32,253
InvokanaCanagliflozin33$27,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$210,342$821,250754 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$65,772$579,418495 claims
AstraZenecaFarxiga$68,197$267,553245 claims
Boehringer IngelheimJardiance, Tradjenta$1,405$168,884175 claims
Mannkind CorporationAfrezza$9,515$101,84835 claims
Chiesi USA, Inc.Mycapssa$16,226$72,72115 claims
MerckJanuvia, Janumet$454$54,16560 claims
Johnson & JohnsonInvokana$25,298$27,45133 claims
BayerKerendia$1,492$26,72032 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$1,195$19,23317 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$111$4,765459 claims
AbbVieSynthroid$841$3,66455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

Other endocrinology, diabetes & metabolism in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →